CGTLive’s Weekly Rewind – January 5, 2024
Review top news and interview highlights from the week ending January 5, 2024.
CGTLive’s Weekly Rewind – January 5, 2024
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. After Exa-Cel: Exploring the Next Wave of CRISPR Gene Editing Strategies
The approval of exa-cel, the first gene editing therapy, may herald a new era in developing gene editing strategies.
2. Alexis Thompson, MD, MPH, on the Simultaneous Approvals of Exa-cel and Lovo-cel For SCD
The chief of hematology at Children’s Hospital of Philadelphia discussed dual approval of the 2 gene therapies that coincided with ASH’s 2023 conference.
3. Pfizer’s Hemophilia B Gene Therapy Approved as Beqvez in Canada
The FDA and EMA have accepted marketing authorization applications and decisions are pending.
4. Piers Blombery, MBBS, PhD, on Looking Deeper Into Effects of CAR T After CAR+ Lymphoma
The associate professor at Peter MacCallum Cancer Centre discussed further research and questions that need to be investigated with the cell therapy.
5. Oncternal Therapeutics Proposes Protocol Changes Following Death of Patient Treated With CAR-T Therapy ONCT-808 in Phase 1/2 Trial
ONCT-808 targets ROR1 and is currently being evaluated for the treatment of r/r aggressive B-cell lymphoma.
Considerations for Administering Hemoglobinopathy Gene Therapies From a Pharmacist’s Perspective
April 20th 2024Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at Mayo Clinic, discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.
